When do you consider local therapies (i.e. TACE) in patients with intrahepatic cholangiocarcinoma who do not tolerate or respond to chemothearpy or who are not surgical candidates?

The treatment of choice would be EBRT, ideally delivered to ablative doses or at least over 80 BED (Tao et al., PMID 26503201).

For LC and OS benefits.

This is an NCCN based recommendation based off of retrospective and single arm prospective (Hong et al., PMID 26668346) data. Two year LC 94% of IHCC...